1. Home
  2. ATYR vs BVS Comparison

ATYR vs BVS Comparison

Compare ATYR & BVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • BVS
  • Stock Information
  • Founded
  • ATYR 2005
  • BVS 2011
  • Country
  • ATYR United States
  • BVS United States
  • Employees
  • ATYR N/A
  • BVS N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • BVS Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • ATYR Health Care
  • BVS Health Care
  • Exchange
  • ATYR Nasdaq
  • BVS Nasdaq
  • Market Cap
  • ATYR 451.3M
  • BVS 432.7M
  • IPO Year
  • ATYR 2015
  • BVS 2021
  • Fundamental
  • Price
  • ATYR $5.35
  • BVS $7.63
  • Analyst Decision
  • ATYR Strong Buy
  • BVS Strong Buy
  • Analyst Count
  • ATYR 5
  • BVS 5
  • Target Price
  • ATYR $23.25
  • BVS $14.40
  • AVG Volume (30 Days)
  • ATYR 5.0M
  • BVS 542.4K
  • Earning Date
  • ATYR 08-07-2025
  • BVS 08-06-2025
  • Dividend Yield
  • ATYR N/A
  • BVS N/A
  • EPS Growth
  • ATYR N/A
  • BVS N/A
  • EPS
  • ATYR N/A
  • BVS 0.03
  • Revenue
  • ATYR N/A
  • BVS $564,142,000.00
  • Revenue This Year
  • ATYR $478.72
  • BVS N/A
  • Revenue Next Year
  • ATYR $1,899.26
  • BVS $6.26
  • P/E Ratio
  • ATYR N/A
  • BVS $277.70
  • Revenue Growth
  • ATYR N/A
  • BVS 5.08
  • 52 Week Low
  • ATYR $1.67
  • BVS $5.81
  • 52 Week High
  • ATYR $7.29
  • BVS $14.38
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 52.99
  • BVS 62.12
  • Support Level
  • ATYR $4.58
  • BVS $7.03
  • Resistance Level
  • ATYR $5.03
  • BVS $7.48
  • Average True Range (ATR)
  • ATYR 0.34
  • BVS 0.43
  • MACD
  • ATYR -0.01
  • BVS 0.05
  • Stochastic Oscillator
  • ATYR 66.09
  • BVS 94.49

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About BVS Bioventus Inc.

Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.

Share on Social Networks: